Treatment of chronic hepatitis C virus infection

Annals of Pharmacotherapy

Volumn 34, Issue 10, 2000, Pages 1156-1164

  Malnick, S D H ^a   Beergabel, M ^a   Lurie, Y ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

Author keywords

Amantadine; Hepatitis; Hepatitis C; Interferon; Nonsteroidal antiinflammatory drugs; Ribavirin; Ursodeoxycholic acid

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; ALPHA1N INTERFERON; ALPHA2A INTERFERON; AMANTADINE; ANTIOXIDANT; CONSENSUS INTERFERON; ENZYME INHIBITOR; GLUCURONIC ACID; GLYCYRRHIZIC ACID; HISTAMINE; INOSINATE DEHYDROGENASE; INTERFERON; KETOPROFEN; MACROGOL; MAXAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTOSTEROL; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; SITOSTEROL; TENOXICAM; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VX 947;

CANCER RISK; CHRONIC HEPATITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; GLYCYRRHIZA; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS; PHLEBOTOMY; PHYTOTHERAPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT PLANNING;

EID: 0033770055     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10017     Document Type: Review

References (82)

1. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
2. Epidemiology of hepatitis C
3. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare
4. Long-term results and complications in renal transplant recipients. Observations in the second decade
5. New perspectives in the diagnosis of hepatitis C
6. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha-interferon. A preliminary report
7. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomized clinical trials
8. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
9. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
10. Influence of pre-treatment factors on outcome of interferon-alpha treatment of patients with chronic hepatitis C
11. HCV-RNA levels play an important role independently of genotype in predicting response to interferon therapy
12. Influence of MHC class II genotype on outcome of infection with hepatitis C virus
13. Molecular evolutionary virology: Its application to hepatitis C virus
14. Factors predictive of a beneficial response to therapy of hepatitis C
15. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta
16. EASL International Consensus Conference on Hepatitis C. Consensus statement
17. Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: Clinical and histological outcome
18. Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: A quantitative histological evaluation
19. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis
20. Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics or nonfibrotics
21. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
22. A comparison of three interferon-alfa 2b regimens for the long-term treatment of chronic non-A, non-B hepatitis
23. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose
24. Use of high-dose interferon in the treatment of chronic hepatitis C
25. Efficacy and tolerance of a 6-month treatment course of dally interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group
26. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
27. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C
28. An escalating dose regimen of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C
29. Treatment of chronic hepatitis C with escalating doses of interferon-alpha 2b increases both biochemical and virologic response
30. Chronic hepatitis C: Interferon treatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP)
31. Chronic hepatitis C vires patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group
32. Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C
33. Natural history of liver fibrosis progression in patients with chronic hepatitis C
34. A randomized controlled trial of maintenance interferon therapy for patients with chronic hepatitis C vires and persistent viremia
35. Multinational evaluation of the efficacy and safety of once-weekly PEGinterferon α-2A (PEG-IFN) in patients with chronic hepatitis C (CHC) with compensated cirrhosis
36. A controlled, randomized, multicenter, descending dose Phase II trial of pegylated interferon alpha-2a (PEG) vs. standard alpha-2a (IFN) for treatment of chronic hepatitis C
37. Molecular mechanisms of action of ribavarin
38. Ribavarin treatment for chronic hepatitis C
39. A pilot study of ribavarin therapy for chronic hepatitis C
40. Tolerance and efficacy of oral ribavarin treatment of chronic hepatitis C: A multicenter trial
41. Interferon alfa-2b alone or in combination with ribavarin as initial treatment for chronic hepatitis C
42. Treatment of naive patients with chronic hepatitis C
43. Randomized trial of interferon alfa-2b and ribavarin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
44. Interferon alpha-2b alone or in combination with ribavarin for the treatment of relapse of chronic hepatitis C
45. Racial differences in responses to therapy with interferon in chronic hepatitis C
46. Role of virion M2 protein in influenza virus uncoating: Specific reduction in the rate of membrane fusion between vires and liposomes by amantadine
47. Treatment of chronic hepatitis C with amantadine
48. The roles of amantadine, rimantadine, ursodeoxycholic acid and NSAIDs alone, or in combination with alpha interferons, in the treatment of chronic hepatitis C
49. Amantadine HCl alone and associated with recombinant alpha IFN 2a during a short term therapy in chronic HCV infection
50. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders
51. A comparison of combination therapy with interferon and ribavarin vs. interferon and amantadine in interferon non-responders with chronic hepatitis C
52. Triple antiviral therapy for chronic hepatitis C in interferon alfa non-responders: A pilot randomized controlled study
53. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C
54. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled trial in 80 patients
55. Long-term efficacy of interferon-a and ursodeoxycholic acid in treatment of chronic type C hepatitis
56. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: A randomized clinical trial with long-term follow up
57. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis
58. Efficacy of ursodeoxycholic acid in combination with interferon-a in treating chronic hepatitis C: Results of a long-term follow-up trial
59. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum gamma-glutamyl transpeptidase levels
60. 2 production by cultured liver biopsy in patients with chronic viral hepatitis: Can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon?
61. Tenoxicam, a non-steroidal anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon
62. Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C
63. Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics, or nonfibrotics
64. Hepatitis C: Epidemiology and review of complementary/alternative medicine treatments
65. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients
66. Acute and chronic hepatitis steatosis leads to in vivo lipid peroxidation in mice
67. N-Acetylcysteine enhances the response to interferon-alpha in chronic hepatitis C: A pilot study
68. The long-term efficacy of glycyrrhizin in chronic hepatitis patients
69. Measurements of iron status in patients with chronic hepatitis
70. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C
71. Clonal analysis of the effect of iron on human cytotoxic and proliferating T lymphocytes
72. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron
73. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C
74. Iron and chronic viral hepatitis
75. Response to interferon alpha therapy is influenced by the iron content of the liver
76. Histamine and cytokine therapy
77. Histamine and the resposne to IFN-alpha in chronic hepatitis C
78. A Phase II dose-ranging study of histamine dihydrochloride (Maxamine) and interferon-alpha-2b as a new therapy for chronic hepatitis C: A 12-week interim analysis
79. Future options for the management of hepatitis C
80. Dose-ranging study of VX-497, a novel, oral IMPDH inhibitor, in patients with hepatitis C
81. Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells